Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bodkin, J. A. Articles by Amsterdam, J. D. Search for Related Content PubMed Citation Articles by Bodkin, J. A. Articles by Amsterdam, J. D. Depression Anticonvulsants

Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients

OBJECTIVE: The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder. METHOD: Following a 1-week placebo lead-in, 177 adult outpatients with major depressive disorder were randomly assigned to receive transdermal selegiline (20 mg applied once daily by means of a 20-cm² patch) (N=89) or placebo (N=88) for 6 weeks. The patients followed a tyramine-restricted diet during the medication trial and for 2 weeks after completion of treatment. Response to medication or placebo was measured by using the 17-item and 28-item versions of the Hamilton Depression Rating Scale, the Montgomery-Åsberg Depression Rating Scale, and the Clinical Global Impression (CGI) severity and improvement measures. RESULTS: Greater improvement was observed after 6 weeks in patients treated with transdermal selegiline than in those given placebo according to all measures. A statistically significant difference between drug and placebo was seen in Hamilton depression scale and Montgomery-Åsberg Depression Rating Scale scores as early as week 1 of treatment. There were no differences in the adverse event profile of the patients given selegiline and those given placebo with the exception of application-site reactions, which were more common with the selegiline transdermal system. No orthostatic hypotensive or hypertensive reactions were observed. CONCLUSIONS: Transdermal selegiline (20 mg applied once daily by means of a 20-cm² patch) administered for 6 weeks was an effective and well-tolerated treatment for adult outpatients with major depression. The typical side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not observed.

This article has been cited by other articles:

				C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]

				A. J. Azzaro, J. Ziemniak, E. Kemper, B. J. Campbell, and C. VanDenBerg Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules J. Clin. Pharmacol., October 1, 2007; 47(10): 1256 - 1267. [Abstract] [Full Text] [PDF]

				A. J. Azzaro, C. M. VanDenBerg, J. Ziemniak, E. M. Kemper, L. F. Blob, and B. J. Campbell Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers J. Clin. Pharmacol., August 1, 2007; 47(8): 978 - 990. [Abstract] [Full Text] [PDF]

				A. J. Azzaro, J. Ziemniak, E. Kemper, B. J. Campbell, and C. VanDenBerg Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications J. Clin. Pharmacol., February 1, 2007; 47(2): 146 - 158. [Abstract] [Full Text] [PDF]

				A. J. Azzaro, C. M. VanDenBerg, L. F. Blob, E. M. Kemper, M. Sharoky, D. A. Oren, and B. J. Campbell Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects. J. Clin. Pharmacol., August 1, 2006; 46(8): 933 - 944. [Abstract] [Full Text] [PDF]

				M. D. Murray and C. M. Callahan Improving Medication Use for Older Adults: An Integrated Research Agenda Ann Intern Med, September 2, 2003; 139(5_Part_2): 425 - 429. [Abstract] [Full Text] [PDF]

				E. Benedictis 20mg transdermal selegiline daily may be effective and well tolerated in adults with major depression Evid. Based Ment. Health, May 1, 2003; 6(2): 44 - 44. [Full Text] [PDF]

				J. Rosack Transdermal Patch Could Herald Renewed Popularity for MAOIs Psychiatr News, December 6, 2002; 37(23): 43 - 43. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us